Recombinant human thrombopoietin in myelosuppressive chemotherapy

ONCOLOGY

Volumn 15, Issue 7 SUPPL. 8, 2001, Pages 35-38

  Vadhan Raj, Saroj ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; RECOMBINANT PROTEIN; THROMBOPOIETIN;

ARTICLE; BONE MARROW; CHEMICALLY INDUCED DISORDER; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFECT; HUMAN; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC PROTOCOLS; BONE MARROW; CARBOPLATIN; CLINICAL TRIALS; HUMANS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 0035403575     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Demetri GD, Vadhan-Raj S: Hematopoietic growth factors, in Pazdur R, Coia L, Hoskins W, Wagman L (eds): Cancer Management: A Multidisciplinary Approach, 4th ed, pp 747-761. Melville, New York, PRR, Inc, 2000.
2. Graydes LA, Freireich EJ, Mantel N: The quantitative correlation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 266:905-909, 1962.
3. Vadhan-Raj S, Kudelka AP, Garrison L, et al: Effects of interleukin-1 alpha on carboplatininduced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol 12:704-714, 1994.
4. D'Hondt V, Weynants P, Humblet Y, et al: Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase II study. J Clin Oncol 11:2063-2071, 1993.